Diagnosing diseases is basically the frontlines when it comes to fighting against illnesses and how effectively and efficiently this is done will affect how the rest of the battle goes. Unfortunately, diagnosis can be expensive, depending on the disease. Thanks to a new microchip, which can cost only $0.1 to create, this might not be a problem anymore.
The microchip in question was created by a team of engineers from Stanford who published their findings in the Proceedings of the National Academy of Sciences. Not only is the chip tiny, it’s also incredibly inexpensive to produce and can be manufactured at a large scale in a very short period of time.
“For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability,” the paper reads. “To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform.”
Calling it the FNIP chip, the researchers created the device with three layers of varying expendability. As for how it is used, it’s basically a two-step process. First, the user would need to customize the configuration in order to suit the particular disease that needs to be diagnosed, Futurism reports. Next, the necessary samples for analysis can then be printed onto the top layer of the chip.
So, which diseases can this microchip detect? So far, the researchers tested it to analyze cancer fluid and succeeded. They also used it to diagnose immune cells and was able to pull off similar results as another diagnostic tool that would have cost $100,000 in comparison.
Before anyone gets too excited, however, the researchers are saying that it would take some time before the microchip becomes widely available. There are some hurdles to overcome first, including more tests to see if the platform is even safe to use.


Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Banks Consider $38 Billion Funding Boost for Oracle, Vantage, and OpenAI Expansion
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
AI-Guided Drones Transform Ukraine’s Battlefield Strategy
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Apple Alerts EU Regulators That Apple Ads and Maps Meet DMA Gatekeeper Thresholds
TSMC Accuses Former Executive of Leaking Trade Secrets as Taiwan Prosecutors Launch Investigation
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO
Apple Leads Singles’ Day Smartphone Sales as iPhone 17 Demand Surges
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
Intel Boosts Malaysia Operations with Additional RM860 Million Investment
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 



